Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy.
暂无分享,去创建一个
M. Banerjee | D. Grignon | J. Lam | W. Sakr | D. Wood | M. Cher | J. Pontes | F. Bianco | L. Davis | M. L. Cher | Mousumi Banerjee
[1] M. Banerjee,et al. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Stalteri,et al. Imaging prostate cancer with technetium-99m-7E11-C5.3 (CYT-351). , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[3] A. Partin,et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. , 1997, The Urologic clinics of North America.
[4] J. Oesterling,et al. Using prostate-specific antigen to eliminate the staging radionuclide bone scan. , 1997, The Urologic clinics of North America.
[5] R. Bahnson,et al. Preliminary imaging results using In-111 labeled CYT-356 (Prostascint) in the detection of recurrent prostate cancer. , 1996, Clinical nuclear medicine.
[6] T. Wheeler,et al. Workgroup 2: Staging and reporting of prostate cancer‐‐Sampling of the radical prostatectomy specimen , 1996, Cancer.
[7] N. Smith,et al. The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. , 1995, The Journal of urology.
[8] Oesterling Je,et al. Patient evaluation if prostate-specific antigen becomes elevated following radical prostatectomy or radiation therapy. , 1994 .
[9] A. Partin,et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. , 1994, Urology.
[10] J. Oesterling,et al. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. , 1993, JAMA.
[11] I. Eardley,et al. Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer. , 1992, British journal of urology.
[12] M. Terris,et al. Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[13] J. Oesterling,et al. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. , 1991, The Journal of urology.
[14] W. Catalona,et al. Clinical use of prostate specific antigen in patients with prostate cancer. , 1989, The Journal of urology.
[15] E. Messing,et al. Prostate specific antigen: not detectable despite tumor progression after radical prostatectomy. , 1989, The Journal of urology.
[16] R. Vessella,et al. The value of serum prostate specific antigen determinations before and after radical prostatectomy. , 1989, The Journal of urology.
[17] H. Pendergrass,et al. Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate. , 1976, Radiology.
[18] M. Potsaid,et al. Accuracy of 99mTC-diphosphonate bone scans and roentgenograms in the detection of prostate, breast and lung carcinoma metastases. , 1975, The American journal of roentgenology, radium therapy, and nuclear medicine.